
## Franco Cavalot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3626211/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Independent association of atherogenic dyslipidaemia with allâ€cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. Cardiovascular Diabetology, 2021, 20, 28.	2.7	6
2	Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMC Medicine, 2021, 19, 66.	2.3	32
3	Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 282-291.	1.1	44
4	Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Research and Care, 2020, 8, e001481.	1.2	22
5	Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia. International Journal of Molecular Sciences, 2020, 21, 4983.	1.8	10
6	Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. Journal of Clinical Medicine, 2020, 9, 246.	1.0	2
7	Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. Thrombosis Research, 2019, 180, 74-85.	0.8	8
8	ls resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. BMC Medicine, 2019, 17, 83.	2.3	9
9	Haemoglobin A1c variability is a strong, independent predictor of allâ€cause mortality in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1885-1893.	2.2	45
10	Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetologica, 2018, 55, 603-612.	1.2	33
11	Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. BioMed Research International, 2018, 2018, 1-11.	0.9	50
12	Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts. Frontiers in Physiology, 2018, 9, 875.	1.3	18
13	Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia, 2018, 61, 2277-2289.	2.9	83
14	Platelets, diabetes and myocardial ischemia/reperfusion injury. Cardiovascular Diabetology, 2017, 16, 71.	2.7	73
15	Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thrombosis and Haemostasis, 2017, 117, 1115-1128.	1.8	61
16	Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetologica, 2015, 52, 971-981.	1.2	8
17	Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. Medicinal Research Reviews, 2015, 35, 968-1031.	5.0	43
18	Resistant hypertension in patients with type 2 diabetes. Journal of Hypertension, 2014, 32, 2401-2410.	0.3	35

FRANCO CAVALOT

#	Article	IF	CITATIONS
19	Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovascular Diabetology. 2014, 13, 59.	2.7	24
20	Leptin and Vascular Smooth Muscle Cells. Current Pharmaceutical Design, 2014, 20, 625-634.	0.9	30
21	HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2301-2310.	4.3	130
22	Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Cardiovascular Diabetology, 2013, 12, 98.	2.7	61
23	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2100-2105.	1.8	92
24	Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. Journal of the American Geriatrics Society, 2013, 61, 1253-1261.	1.3	65
25	Rate and Determinants of Association Between Advanced Retinopathy and Chronic Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2317-2323.	4.3	106
26	Pathogenetic Mechanisms and Cardiovascular Risk. Diabetes Care, 2012, 35, 2607-2612.	4.3	36
27	High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Research and Clinical Practice, 2012, 98, 329-337.	1.1	29
28	High Glucose Inhibits the Aspirin-Induced Activation of the Nitric Oxide/cGMP/cGMP-Dependent Protein Kinase Pathway and Does Not Affect the Aspirin-Induced Inhibition of Thromboxane Synthesis in Human Platelets. Diabetes, 2012, 61, 2913-2921.	0.3	27
29	Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: Influence of insulin resistance and oxidative stress. Atherosclerosis, 2011, 216, 44-53.	0.4	40
30	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. Atherosclerosis, 2011, 218, 194-199.	0.4	55
31	Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. Journal of Hypertension, 2011, 29, 1802-1809.	0.3	198
32	Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up. Diabetes Care, 2011, 34, 2237-2243.	4.3	264
33	In Central Obesity, Weight Loss Restores Platelet Sensitivity to Nitric Oxide and Prostacyclin. Obesity, 2010, 18, 788-797.	1.5	59
34	Evaluation of a simple policy for pre- and post-prandial blood glucose self-monitoring in people with type 2 diabetes not on insulin. Diabetes Research and Clinical Practice, 2010, 87, 246-251.	1.1	50
35	Does Pancreatic Elastase-1 in Stools Predict Steatorrhea in Type 1 Diabetes?. Diabetes Care, 2006, 29, 719-721.	4.3	24
36	Pancreatic Elastase-1 in Stools, a Marker of Exocrine Pancreas Function, Correlates With Both Residual Â-Cell Secretion and Metabolic Control in Type 1 Diabetic Subjects: Response to Mueller et al Diabetes Care, 2005, 28, 2810-2811.	4.3	1

FRANCO CAVALOT

#	Article	IF	CITATIONS
37	Pancreatic Elastase-1 in Stools, a Marker of Exocrine Pancreas Function, Correlates With Both Residual Â-Cell Secretion and Metabolic Control in Type 1 Diabetic Subjects. Diabetes Care, 2004, 27, 2052-2054.	4.3	55
38	White Blood Cell Count Is Positively Correlated With Albumin Excretion Rate in Subjects With Type 2 Diabetes. Diabetes Care, 2002, 25, 2354-2355.	4.3	29
39	Adenosine increases human platelet levels of 3′,5′-cGMP through nitric oxide. Thrombosis Research, 2002, 105, 71-78.	0.8	75
40	Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thrombosis Research, 2002, 107, 31-37.	0.8	16
41	Studies on Inhibition of Human Platelet Function by Sodium Nitroprusside. Kinetic Evaluation of the Effect on Aggregation and Cyclic Nucleotide Content. Thrombosis Research, 2001, 102, 319-330.	0.8	18
42	N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. European Journal of Clinical Investigation, 2001, 31, 452-461.	1.7	39
43	Modulation of human platelet function by l-canavanine Differential effects of low and high concentrations. General Pharmacology, 1999, 32, 321-328.	0.7	9
44	Influence of protamine on adhesion, chemotaxis and proliferation of human vascular smooth muscle cells. Diabetologia, 1997, 40, 67-75.	2.9	9
45	Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations. Thrombosis Research, 1996, 82, 57-68.	0.8	18
46	Nonenzymatic glycation of fibronectin impairs adhesive and proliferative properties of human vascular smooth muscle cells. Metabolism: Clinical and Experimental, 1996, 45, 285-292.	1.5	12
47	Interplay between milrinone and adenosine in the inhibition of human platelet response. General Pharmacology, 1996, 27, 1149-1154.	0.7	18
48	GLYCERYL TRINITRATE ENHANCES THE ADENOSINE-INDUCED INHIBITION OF PLATELET RESPONSES: A MECHANISM POTENTIALLY INVOLVED IN THE IN VIVO ANTI-AGGREGATING EFFECTS OF ORGANIC NITRATES. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 803-811.	0.9	7
49	Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. Thrombosis Research, 1995, 77, 399-410.	0.8	4
50	Effects of forskolin and organic nitrate on aggregation and intracellular cyclic nucleotide content in human platelets. General Pharmacology, 1994, 25, 1093-1100.	0.7	15
51	Insulin Increases Guanosine-3′ ,5′-Cyclic Monophosphate in Human Platelets: A Mechanism Involved in the Insulin Anti-Aggregating Effect. Diabetes, 1994, 43, 1015-1019.	0.3	60
52	Effect of dopamine on adenosine 3′,5′-cyclic monophosphate levels in human platelets. General Pharmacology, 1993, 24, 435-438.	0.7	8
53	STUDIES ON THE EFFECT OF DOPAMINE ON THE HUMAN PLATELET RESPONSE. Clinical and Experimental Pharmacology and Physiology, 1992, 19, 613-618.	0.9	12
54	Antibodies in rabbits immunized with cationized IgG react with histones H3 and H4. Arthritis and Rheumatism, 1992, 35, 1218-1226.	6.7	4

FRANCO CAVALOT

#	Article	IF	CITATIONS
55	Phenothiazines inhibit collagen-induced thromboxane B2 synthesis and increase forskolin anti-aggregating effects in human platelets. General Pharmacology, 1991, 22, 773-778.	0.7	5
56	CALCIUM-CHANNEL BLOCKING AGENTS VERAPAMIL AND DILTIAZEM ARE INHIBITORS OF VASOPRESSIN-INDUCED HUMAN PLATELET ACTIVATION. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 767-773.	0.9	6
57	Studies on inhibition of human platelet response by diltiazem. General Pharmacology, 1990, 21, 949-954.	0.7	7
58	Insulin influences the renin-angiotensin-aldosterone system in humans. Metabolism: Clinical and Experimental, 1989, 38, 501-503.	1.5	74
59	DEXTROSE INFUSION BY ARTIFICIAL PANCREAS IN DIAGNOSIS OF INSULINOMA. Lancet, The, 1982, 319, 631-632	. 6.3	7
60	To what extent does the artificial pancreas facilitate the surgery of preoperatively not localized insulinomas?. Acta Diabetologica Latina, 1982, 19, 385-390.	0.2	1